Silvia Perra
Research Subjects
Silvia Perra has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Gianluca Perseghin
Department of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, Italy
3 shared publications - Emanuele Muraca
Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy
2 shared publications - Guido Lattuada
Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy
2 shared publications - Stefano Ciardullo
Department of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, Italy
2 shared publications A. Oltolini
Metabolic Medicine, Department of Internal Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy
1 shared publicationAlice Oltolini
Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy
1 shared publication
Latest Publications
- Open Access
- 7 November 2022
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 21 (1) , 1-9
NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population
Background: Even though hyperglycemia is a well-known cardiovascular risk factor, the absolute risk of cardiovascular events varies to a great extent within each glycemic category. The aim of this study is to evaluate whether N-terminal pro-B natriuretic peptide (NT-ProBNP) could help identify subjects at higher cardiovascular risk, independently of blood glucose levels. Methods: Serum NT-ProBNP levels were measured in 5502 people aged 45–79 years without heart failure from the general population (3380 with normoglycemia, 1125 with pre-diabetes and 997 with diabetes) that participated in the 1999–2004 cycles of the National Health and Nutrition Examination Survey. We applied Cox and Fine Gray models adjusted for cardiovascular risk factors to evaluate the association between NT-ProBNP levels and all-cause and cardiovascular mortality through December 2015. Results: After a median follow-up of 13 years, 1509 participants died, 330 of cardiovascular causes. In the multivariable-adjusted models, compared with participants with NT-ProBNP < 100 pg/ml, those with levels 100–300 pg/ml and ≥ 300 pg/ml had a higher incidence of both all-cause mortality (HR 1.61, 95% CI 1.12–2.32, p = 0.012 and HR 2.96, 95% CI 1.75–5.00, p < 0.001, respectively) and cardiovascular mortality (HR 1.57, 95% CI 1.17–2.10, p = 0.011 and HR 2.08, 95% CI 1.47–2.93, p < 0.001, respectively). The association was consistent in subgroup analyses based on glycemic status, obesity, age and sex. Conclusions: Elevated NT-ProBNP is independently associated with all-cause and cardiovascular mortality in the general population and could help identify patients at the highest risk. Further studies are needed to evaluate whether intensification of treatment based on biomarker data might lead to improvements in cardiovascular risk reduction.
- 7 November 2022
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 21 (1) , 1-9
Open AccessNT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population
Background: Even though hyperglycemia is a well-known cardiovascular risk factor, the absolute risk of cardiovascular events varies to a great extent within each glycemic category. The aim of this study is to evaluate whether N-terminal pro-B natriuretic peptide (NT-ProBNP) could help identify subjects at higher cardiovascular risk, independently of blood glucose levels. Methods: Serum NT-ProBNP levels were measured in 5502 people aged 45–79 years without heart failure from the general population (3380 with normoglycemia, 1125 with pre-diabetes and 997 with diabetes) that participated in the 1999–2004 cycles of the National Health and Nutrition Examination Survey. We applied Cox and Fine Gray models adjusted for cardiovascular risk factors to evaluate the association between NT-ProBNP levels and all-cause and cardiovascular mortality through December 2015. Results: After a median follow-up of 13 years, 1509 participants died, 330 of cardiovascular causes. In the multivariable-adjusted models, compared with participants with NT-ProBNP < 100 pg/ml, those with levels 100–300 pg/ml and ≥ 300 pg/ml had a higher incidence of both all-cause mortality (HR 1.61, 95% CI 1.12–2.32, p = 0.012 and HR 2.96, 95% CI 1.75–5.00, p < 0.001, respectively) and cardiovascular mortality (HR 1.57, 95% CI 1.17–2.10, p = 0.011 and HR 2.08, 95% CI 1.47–2.93, p < 0.001, respectively). The association was consistent in subgroup analyses based on glycemic status, obesity, age and sex. Conclusions: Elevated NT-ProBNP is independently associated with all-cause and cardiovascular mortality in the general population and could help identify patients at the highest risk. Further studies are needed to evaluate whether intensification of treatment based on biomarker data might lead to improvements in cardiovascular risk reduction.
- Open Access
- 1 February 2020
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 13, 489-497
Resting Whole Body Energy Metabolism in Class 3 Obesity; from Preserved Insulin Sensitivity to Overt Type 2 Diabetes
Context: Insulin resistance and diabetes may influence separately or in combination whole body energy metabolism. Objective: To assess the impact of insulin resistance and/or overt type 2 diabetes on resting energy expenditure (REE) in class 3 obese individuals. Design and Setting: Retrospective, cross-sectional analysis of a set of data about individuals attending the outpatients service of a single center of bariatric surgery between January 2015 and December 2017. Patients: We screened 382 patients in which abnormal thyroid function was excluded, and segregated them in three groups of subjects: patients with type 2 diabetes (T2DM; n=70), non-diabetic insulin-resistant patients with HOMA-IR ≥ 3 (n=236), non-diabetic insulin-sensitive patients with HOMA-IR < 3 (n=75). Main Outcome Measure: Resting energy expenditure (REE), body composition and insulin resistance assessed using indirect calorimetry, bioimpedance and HOMA-IR. Results: Non-diabetic insulin-sensitive patients resulted to be younger, with lower BMI and higher prevalence of female subjects; meanwhile, non-diabetic but insulin-resistant patients and T2DM patients were not different in terms of anthropometric parameters. REE was higher in T2DM than in non-diabetic insulin-resistant and insulin-sensitive individuals when expressed as percent of the predicted REE (based on Harris Benedict equation) (p< 0.0001) or when adjusted for kg of free fat mass (p< 0.0001) and was found to be higher also in insulin-resistant vs insulin-sensitive patients (p< 0.001). The respiratory quotient was different between groups (0.87± 0.11, 0.86± 0.12 and 0.91± 0.14 in T2DM, insulin-resistant and insulin-sensitive patients, respectively; p< 0.03). Regression analysis confirmed that HOMA-IR was independently associated with the REE (R2=0.110, p< 0.001). Conclusion: Class 3 obese patients with normal insulin sensitivity are characterized by reduced fasting REE in comparison to insulin-resistant obese patients and obese patients with short duration of diabetes supporting the hypothesis that down-regulation of nutrients’ oxidative disposal may represent an adaptation of energy metabolism in obese individuals with preserved insulin sensitivity.
- 1 February 2020
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 13, 489-497
Open AccessResting Whole Body Energy Metabolism in Class 3 Obesity; from Preserved Insulin Sensitivity to Overt Type 2 Diabetes
Context: Insulin resistance and diabetes may influence separately or in combination whole body energy metabolism. Objective: To assess the impact of insulin resistance and/or overt type 2 diabetes on resting energy expenditure (REE) in class 3 obese individuals. Design and Setting: Retrospective, cross-sectional analysis of a set of data about individuals attending the outpatients service of a single center of bariatric surgery between January 2015 and December 2017. Patients: We screened 382 patients in which abnormal thyroid function was excluded, and segregated them in three groups of subjects: patients with type 2 diabetes (T2DM; n=70), non-diabetic insulin-resistant patients with HOMA-IR ≥ 3 (n=236), non-diabetic insulin-sensitive patients with HOMA-IR < 3 (n=75). Main Outcome Measure: Resting energy expenditure (REE), body composition and insulin resistance assessed using indirect calorimetry, bioimpedance and HOMA-IR. Results: Non-diabetic insulin-sensitive patients resulted to be younger, with lower BMI and higher prevalence of female subjects; meanwhile, non-diabetic but insulin-resistant patients and T2DM patients were not different in terms of anthropometric parameters. REE was higher in T2DM than in non-diabetic insulin-resistant and insulin-sensitive individuals when expressed as percent of the predicted REE (based on Harris Benedict equation) (p< 0.0001) or when adjusted for kg of free fat mass (p< 0.0001) and was found to be higher also in insulin-resistant vs insulin-sensitive patients (p< 0.001). The respiratory quotient was different between groups (0.87± 0.11, 0.86± 0.12 and 0.91± 0.14 in T2DM, insulin-resistant and insulin-sensitive patients, respectively; p< 0.03). Regression analysis confirmed that HOMA-IR was independently associated with the REE (R2=0.110, p< 0.001). Conclusion: Class 3 obese patients with normal insulin sensitivity are characterized by reduced fasting REE in comparison to insulin-resistant obese patients and obese patients with short duration of diabetes supporting the hypothesis that down-regulation of nutrients’ oxidative disposal may represent an adaptation of energy metabolism in obese individuals with preserved insulin sensitivity.
- 1 September 2017
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 35 (Supplement) , e219-e220
[PP.16.07] CVD RISK IS INDEPENDENTLY ASSOCIATED WITH VISIT-TO-VISIT VARIABILITY OF SYSTOLIC BLOOD PRESSURE (BP) IN PATIENTS WITH TYPE 2 DIABETES
Objective: Recent evidence suggest that CVD risk is related also on the consistency of BP control between on-treatment visits. Visit-to-visit variability of systolic BP is a biomarker of arterial stiffness, autonomic dysfunction, endothelial damage and systemic inflammation but it may also reflect poor patients’ adherence to the pharmacologic therapy. Design and method: We analyzed the relationships between micro-and macro-vascular complications of diabetes in 818 patients attending at least four times our secondary care diabetes clinic between 2013–15 with the standard deviation of the visit-to-visit variability of sitting systolic BP. We segregated these patients in tertiles of the standard deviation of visit-to-visit variability. Results: Patients with the high visit-to-visit variability were older (p < 0.0001), with higher waist circumference (p < 0.022), higher systolic (136 ± 17, 138 ± 15 and 142 ± 14 mm Hg; p < 0.0001), but not diastolic (79 ± 9, 78 ± 10 and 78 ± 9 mm Hg; p = 0.56) blood pressure and heart rate (78 ± 12, 78 ± 10 and 77 ± 9; p = 0.32). Glycemic control was not different between tertiles, meanwhile estimated GFR was lower in the tertile with high visit-to-visit variability of BP (p < 0.0001). Diabetic retinopathy (19%, 17% and 26%; p < 0.05) but not microalbuminuria (32%, 36% and 37%; p < 0.48) was more frequent in those with high visit-to-visit variability of BP. Established CVD was more prevalent in patients with high variability (35%, 50%, 72%; p < 0.0001). Treatments with statin (61%, 76% and 74%; p < 00001) and anti-hypertensive drugs (ACE-inhibitors and Ca antagonists in particular) were also more frequent in patients with high variability. When multivariate analysis of regression was performed with the 10 year UKPDS Risk Engine used as dependent variable, visit-to-visit variability of BP was independently associated with the risks of coronary heart disease, fatal CHD, and more tightly with the risks of stroke and fatal stroke also when adjusted for max systolic blood pressure and drug therapy. Conclusions: The results of this analysis support the hypothesis that in patient with type 2 diabetes a lack of stable control of ambulatory BP is related to established CVD and increased risk of CVD events.
- 1 September 2017
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 35 (Supplement) , e219-e220
[PP.16.07] CVD RISK IS INDEPENDENTLY ASSOCIATED WITH VISIT-TO-VISIT VARIABILITY OF SYSTOLIC BLOOD PRESSURE (BP) IN PATIENTS WITH TYPE 2 DIABETES
Objective: Recent evidence suggest that CVD risk is related also on the consistency of BP control between on-treatment visits. Visit-to-visit variability of systolic BP is a biomarker of arterial stiffness, autonomic dysfunction, endothelial damage and systemic inflammation but it may also reflect poor patients’ adherence to the pharmacologic therapy. Design and method: We analyzed the relationships between micro-and macro-vascular complications of diabetes in 818 patients attending at least four times our secondary care diabetes clinic between 2013–15 with the standard deviation of the visit-to-visit variability of sitting systolic BP. We segregated these patients in tertiles of the standard deviation of visit-to-visit variability. Results: Patients with the high visit-to-visit variability were older (p < 0.0001), with higher waist circumference (p < 0.022), higher systolic (136 ± 17, 138 ± 15 and 142 ± 14 mm Hg; p < 0.0001), but not diastolic (79 ± 9, 78 ± 10 and 78 ± 9 mm Hg; p = 0.56) blood pressure and heart rate (78 ± 12, 78 ± 10 and 77 ± 9; p = 0.32). Glycemic control was not different between tertiles, meanwhile estimated GFR was lower in the tertile with high visit-to-visit variability of BP (p < 0.0001). Diabetic retinopathy (19%, 17% and 26%; p < 0.05) but not microalbuminuria (32%, 36% and 37%; p < 0.48) was more frequent in those with high visit-to-visit variability of BP. Established CVD was more prevalent in patients with high variability (35%, 50%, 72%; p < 0.0001). Treatments with statin (61%, 76% and 74%; p < 00001) and anti-hypertensive drugs (ACE-inhibitors and Ca antagonists in particular) were also more frequent in patients with high variability. When multivariate analysis of regression was performed with the 10 year UKPDS Risk Engine used as dependent variable, visit-to-visit variability of BP was independently associated with the risks of coronary heart disease, fatal CHD, and more tightly with the risks of stroke and fatal stroke also when adjusted for max systolic blood pressure and drug therapy. Conclusions: The results of this analysis support the hypothesis that in patient with type 2 diabetes a lack of stable control of ambulatory BP is related to established CVD and increased risk of CVD events.